The United Kingdom and the United States have reached a key bilateral deal that will ensure zero tariffs on British medicine products entering the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to boost expenditure on drugs through the public health system. This pledge secures that duties on these vital exports will be held at zero for a timeframe of the next three years.
This agreement follows recent warnings to significantly raise duties on branded pharmaceutical imports, with figures discussed up to 100%.
"This deal with the United Kingdom reinforces the global environment for cutting-edge drugs and establishes long-overdue equity to American-British pharmaceutical trade," a statement declared.
Economic Importance
Medicines represent one of the the United Kingdom's most significant exports to the US, which is easily the primary market for large British pharmaceutical firms.
Statistics indicate that in the year to the end of last September, the UK sold medicines worth £11.1bn to the US. This figure made up 17.4% of British export trade in that timeframe.
"This guarantee secures work, increases funding and sets the stage for the UK to become a international leader for life sciences," a government official stated.
Specific NHS Changes
The pact includes several notable commitments from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new treatments to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise total health service expenditure on drugs from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Payback Limit: The sum manufacturers must pay back to the NHS to stay within budget will be restricted at fifteen percent. Last year, repayments were more than 20%.
Industry Background
The pact comes amid a protracted tension between the sector and the ministers over medicine costs and approval rates.
This friction were exacerbated by claims that American consumers were charged several times more for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or abandoned, while major expansions have been pledged toward American operations.
The Science Minister stated that the NHS needed to increase expenditure on treatments, noting that its budget allocation on drugs had shrunk as a proportion of its resources over the last ten years.
